GSK’s vaccine sales in China reflect broader pressures facing multinational pharma firms in the Chinese market. In December 2024, GSK’s Chinese distribution deal for Shingrix with Chongqing Zhifei ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical ... applications for depemokimab have been accepted for review by the China National Medical (TASE:PMCN) Products Administration and submitted ...

The verdict follows investigations initiated by China's Ministry of Public Security in June 2013. GSKCI will pay a fine of £297 million (3 billion RMB) to the Chinese Government, which will be ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications for depemokimab ...